Table 1.
HSCT pairs, diseases, transplantation characteristics, and outcome
| Characteristics | Values |
|---|---|
| Recipients (n = 452) | |
| Median age, years (y) | 52 |
| Younger than 20 y, n (%) | 7 (1.5) |
| 20 to 40 y, n (%) | 72 (15.9) |
| Older than 40 y, n (%) | 373 (82.5) |
| Male, n (%) | 275 (60.8) |
| MICA-129 genotype frequencies | |
| Val/Val, n (%) | 232 (51.3) |
| Met/Val, n (%) | 161 (35.6) |
| Met/Met, n (%) | 59 (13.1) |
| MICA-129 allele frequencies | |
| Val, n (%) | 625 (69.1) |
| Met, n (%) | 279 (30.9) |
| Underlying diagnosis | |
| Acute leukemia, n (%) | 180 (39.8) |
| Hodgkin lymphoma, non-Hodgkin lymphoma, n (%) | 165 (36.5) |
| Multiple myeloma, n (%) | 49 (10.8) |
| Myelodysplastic syndrome, n (%) | 28 (6.2) |
| Myeloproliferative diseases, chronic myeloid leukemia, n (%) | 15 (3.3) |
| Other diagnoses, n (%) | 15 (3.3) |
| Disease status for malignant disorders | |
| Early, n (%) | 94 (20.8) |
| Intermediate, n (%) | 97 (21.5) |
| Advanced, n (%) | 120 (26.5) |
| NDa, n (%) | 141 (31.2) |
| Donors (n = 452) | |
| Median age, y | 40 |
| Younger than 20 y, n (%) | 2 (0.4) |
| 20 to 40 y, n (%) | 209 (46.2) |
| Older than 40 y, n (%) | 189 (41.8) |
| ND, n (%) | 52 (11.5) |
| Male, n (%) | 283 (62.6) |
| Female, n (%) | 134 (29.6) |
| ND, n (%) | 35 (7.7) |
| Female donor to male recipient, n (%) | 77 (17.0) |
| HLA-matched unrelated donor, n (%) | 307 (67.9) |
| Less than 8/8-matched unrelated donor, n (%) | 68 (15.0) |
| Matched-related donor, n (%) | 143 (31.6) |
| MICA-129 genotype frequencies | |
| Val/Val, n (%) | 224 (49.6) |
| Met/Val, n (%) | 156 (34.5) |
| Met/Met, n (%) | 63 (13.9) |
| ND, n (%) | 9 (2.0) |
| MICA-129 allele frequencies | |
| Val, n (%) | 604 (68.2) |
| Met, n (%) | 282 (31.8) |
| Transplantation | |
| Source of stem cells | |
| Peripheral blood, n (%) | 441 (97.6) |
| Bone marrow, n (%) | 11 (2.4) |
| Busulfan-based conditioning, n (%) | 402 (88.9) |
| Total body irradiation-based conditioning, n (%) | 47 (10.4) |
| Reduced intensity conditioning, n (%) | 170 (37.6) |
| T-cell depletion, n (%) | 252 (55.8) |
| Outcome | |
| Occurrence of acute GVHD, n (%) | 246 (54.4) |
| Grade I to II, n (%) | 159 (35.2) |
| Grade III to IV, n (%) | 87 (19.2) |
| Occurrence of chronic GVHD, n (%) | 138 (30.5) |
| Occurrence of relapse, n (%) | 86 (19.0) |
| Mortality, n (%) | 178 (39.4) |
| Treatment-related mortality (TRM), n (%) | 109 (24.1) |
| Mortality due to acute GVHD, n (%) | 52 (11.5) |
| Infection and other TRM, n (%) | 57 (12.6) |
| Mortality due to relapse, n (%) | 57 (12.6) |
| Unknown reason of mortality, n (%) | 12 (2.7) |
a
ND, missing data or not determined parameters.